Latest & greatest articles for baclofen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on baclofen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on baclofen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for baclofen

1. Baclofen for alcohol withdrawal. Full Text available with Trip Pro

Baclofen for alcohol withdrawal. Baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review published in 2015, Issue 4.To assess the efficacy and safety of baclofen for people with AWS.We updated our searches of the following databases to March 2017 (...) : the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL. We also searched registers of ongoing trials. We handsearched the references quoted in the identified trials, and sought information from researchers, pharmaceutical companies, and relevant trial authors about unpublished or uncompleted trials. We placed no restrictions on language.We included all randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for people

2017 Cochrane

2. Baclofen

Baclofen Top results for baclofen - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for baclofen The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

3. Intrathecal baclofen for treating spasticity in children with cerebral palsy. (Abstract)

Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cerebral palsy is a disorder of movement and posture arising from a non-progressive lesion in the developing brain. Spasticity, a disorder of increased muscle tone, is the most common motor difficulty and is associated with activity limitation to varying degrees in mobility and self care.Oral baclofen, a gamma-aminobutyric acid (GABA) agonist, has been used in oral form to treat spasticity for some time, but it has (...) a variable effect on spasticity and the dose is limited by the unwanted effect of excessive sedation. Intrathecal baclofen produces higher local concentrations in cerebrospinal fluid at a fraction of the equivalent oral dose and avoids this excessive sedation.To determine whether intrathecal baclofen is an effective treatment for spasticity in children with cerebral palsy.We searched the CENTRAL, MEDLINE, EMBASE and CINAHL databases, handsearched recent conference proceedings, and communicated

2015 Cochrane

4. Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol consumption: a systematic review and meta-analysis

Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol consumption: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2017 PROSPERO

5. Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury. Full Text available with Trip Pro

Outcomes of intrathecal baclofen therapy in patients with cerebral palsy and acquired brain injury. Intrathecal baclofen (ITB) has been known to reduce spasticity which did not respond to oral medications and botulinum toxin treatment. However, few results have been reported comparing the effects of ITB therapy in patients with cerebral palsy (CP) and acquired brain injury. This study aimed to investigate beneficial and adverse effects of ITB bolus injection and pump therapy in patients with CP

2017 Medicine

6. Alcohol dependence: the risks of high-dose baclofen

Alcohol dependence: the risks of high-dose baclofen Prescrire IN ENGLISH - Spotlight ''Alcohol dependence: the risks of high-dose baclofen '', 1 November 2018 {1} {1} {1} | | > > > Alcohol dependence: the risks of high-dose baclofen Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Alcohol dependence: the risks of high-dose baclofen With high-dose (...) baclofen, there is an increased risk of epilepsy, infection, myocardial infarction or suicidal thoughts. Baclofen has been used as a muscle relaxant since the 1970s. In France, it has also been used orally since the 2000s, at higher doses, to reduce alcohol consumption or to help maintain abstinence among alcohol-dependent patients. At present, its use in alcohol dependence is governed by a temporary recommendation for use issued by the French Health Products Safety Agency (Agence française du

2018 Prescrire

7. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Full Text available with Trip Pro

Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity Bensmail D, Ward AB, Wissel J, Motta F, Saltuari L, Lissens J, Cros S, Beresniak A Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of intrathecal baclofen as a first treatment in the medical management of spasticity, in France. The authors concluded that initial baclofen could be cost-effective compared with usual care. The cost and effectiveness

2009 NHS Economic Evaluation Database.

8. A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Full Text available with Trip Pro

A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Alcohol withdrawal syndrome (AWS) is a distressing condition, generally controlled by benzodiazepines (BZD's). Baclofen, a gamma-aminobutyric acid-B (GABAB) agonist, has also shown promising results in controlling AWS. As there are few studies comparing the efficacy and tolerability of chlordiazepoxide with baclofen (...) , the present study was taken up. The objective of this study was to compare efficacy and tolerability of baclofen with chlordiazepoxide in uncomplicated AWS.Sixty subjects with uncomplicated AWS were randomized into two groups of 30 each, to receive baclofen (30 mg) or chlordiazepoxide (75 mg) in decremented fixed dose regime for 9 days. Clinical efficacy was assessed by Clinical Institute Withdrawal Assessment for Alcohol-Revised Scale (CIWA-Ar) and tolerability by the nature and severity of adverse

2016 Biomedical journal Controlled trial quality: uncertain

9. Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy

Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01386255 Recruitment Status : Withdrawn (No participants were enrolled) First Posted : July 1, 2011 Last Update Posted : August 29, 2017 Sponsor: Boston Children’s Hospital

2011 Clinical Trials

10. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS) Full Text available with Trip Pro

Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS) Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions.'Spasticity In Stroke-Randomised Study' (SISTERS) was a randomised, controlled, open-label, multicentre phase IV study to evaluate the efficacy

2018 EvidenceUpdates

11. Baclofen

Baclofen USE OF BACLOFEN IN PREGNANCY 0344 892 0909 USE OF BACLOFEN IN PREGNANCY (Date of issue: January 2019 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Baclofen is a gamma-aminobutyric acid (GABA) agonist licensed for oral (...) or intrathecal administration to alleviate spasticity of voluntary muscle in patients with multiple sclerosis, spinal cord lesions, cerebral palsy, cerebrovascular accidents, traumatic head injury and meningitis. Data on the use of baclofen in human pregnancy are derived from one small cohort study (presented in abstract only), case reports and two small case series (one presented only in abstract), and as such, are too limited to accurately assess risks to the infant or pregnancy. An increased risk

2014 UK Teratology Information Service

12. Effect of a Combination of Omeprazole Plus Sustained Release Baclofen Versus Omeprazole Alone on Symptoms of Patients with Gastroesophageal Reflux Disease (GERD). Full Text available with Trip Pro

Effect of a Combination of Omeprazole Plus Sustained Release Baclofen Versus Omeprazole Alone on Symptoms of Patients with Gastroesophageal Reflux Disease (GERD). Previous studies have reported the efficacy of baclofen in the treatment of Gastroesophageal Reflux Diseases (GERD). The objective of present study is to evaluate the effect of co-administration of omeprazole 20 mg/d plus sustained Release baclofen (SR baclofen) vs. omeprazole 20 mg/d plus placebo on alleviation of symptoms (...) in patients with a diagnosis of GERD. A prospective, double blind, placebo controlled trial included 60 patients with diagnosis of GERD have been done. Patients were randomly selected to receive either SR baclofen or a placebo in addition to omeprazole 20 mg/d for a period of 2 weeks. Patients were questioned regarding heartburn, regurgitation, chest pain and hoarseness at the base line and after 2 weeks. All patients tolerated the medications and no patients failed to complete the study due to adverse

2015 Iranian journal of pharmaceutical research : IJPR Controlled trial quality: predicted high

13. Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. (Abstract)

Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. Increasing evidence suggests that the function of the GABAergic system is abnormally low in autism spectrum disorder (ASD). Baclofen, which functions as a selective agonist for GABAB receptors, does appear promising for the treatment of ASD. We conducted a 10-week randomized-controlled study aimed at evaluating the potential of baclofen as an adjuvant therapy to enhance the effect of risperidone (...) , hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004). Combined treatment with baclofen and risperidone exerted a greater effect on improvement of hyperactivity symptoms at both midpoint [Cohen's d, 95% confidence interval (CI) = - 3.14, - 5.56 to - 0.72] and endpoint (d, 95% CI = - 4.45, - 8.74 to - 0.16) when compared with treatment with placebo plus risperidone. The two treatments achieved comparable results for other outcome measures. Our data

2019 European child & adolescent psychiatry Controlled trial quality: predicted high

14. What is the evidence for the use of Baclofen in acute muscle spasm and in particular for acute back pain

What is the evidence for the use of Baclofen in acute muscle spasm and in particular for acute back pain What is the evidence for the use of Baclofen in acute muscle spasm and in particular for acute back pain - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document (...) across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com What is the evidence for the use of Baclofen in acute muscle spasm and in particular for acute back pain A 2003 Cochrane systematic review on muscle relaxants for non-specific low-back pain (1) reports

2012 TRIP Answers

15. Pregnancy and Breastfeeding during Intrathecal Baclofen Therapy – A Case Study and Review Full Text available with Trip Pro

Pregnancy and Breastfeeding during Intrathecal Baclofen Therapy – A Case Study and Review We report the case of a young woman who received intrathecal baclofen therapy (ITB) and subsequently became pregnant and had a normal delivery. A 28-year-old woman with flexion myelopathy had anterior decompression with fusion at C4/5 and C5/6 levels. Clinical symptoms improved after surgery. However, when she was 29 years old, her symptoms steadily advanced to Modified Ashworth Scale 3 spasticity level (...) in the lower legs, with pain in both of them and urinary retention tendency. Since a 25 μg intrathecal baclofen injection improved her symptoms, an ITB pump system was implanted. After surgery, lower limb spasticity and urinary retention improved. Two years after ITB pump implantation, the patient married and became pregnant. The patient intended to have normal delivery but the induction of labor was ineffective and childbirth was completed by Cesarean section with lumbar anesthesia. The infant's Apgar

2018 NMC Case Report Journal

16. Baclofen for alcohol withdrawal. (Abstract)

Baclofen for alcohol withdrawal. The treatment of baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. Baclofen is easily manageable, what's more, no patient treated with baclofen reported euphoria or other pleasant effects caused by the drug and no subject reported any degree of craving for the drug.To assess the efficacy and safety of baclofen for patients with alcohol withdrawal syndrome.We searched (...) . All searches included non-English language literature.All randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for patients with AWS. Uncontrolled, non-randomised or quasi-randomised trials were excluded. Both parallel group and cross-over design were included.Two reviewers independently assessed references retrieved for possible inclusion. All disagreements were resolved by an independent party. Study authors were contacted for additional

2011 Cochrane

17. Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia

Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia Malaysian Health Technology Assessment (MaHTAS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Malaysian Health Technology Assessment (MaHTAS). Continuous intrathecal baclofen (ITB) infusion for severe spasticity and dystonia. Putrajaya: Malaysian Health Technology Assessment (MaHTAS). 2014 Authors' objectives To assess the safety, effectiveness, cost-effectiveness, organizational issues related to the use of continuous ITB infusion for treatment of patients with severe spasticity or severe dystonia or having both conditions compared with conventional treatment. Authors' conclusions

2014 Health Technology Assessment (HTA) Database.

18. Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. (Abstract)

Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. Benzodiazepines (BDZs) have been the treatment of choice for alcohol withdrawal syndrome (AWS); however, they are associated with several side effects and also have abuse potential. In some studies, the use of baclofen has been effective in reducing symptoms of alcohol withdrawal symptoms.The objective of this study was to compare the efficacy of baclofen and benzodiazepine (lorazepam) in reducing (...) symptoms of AWS.It was a single-center, randomized, open-label study. Patients with alcohol dependence syndrome were enrolled in the study and randomized into two groups using computer-generated random table number. Baclofen (experimental group, 10 mg three times a day) and BZDs (control group, lorazepam, 8-12 mg/day in divided doses) were orally administered for reducing symptoms of alcohol withdrawal. Both groups received Vitamin B1 (100 mg/day through intramuscular route) and psychotherapeutic

2019 Indian journal of psychiatry Controlled trial quality: uncertain

19. Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures. Full Text available with Trip Pro

Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures. Background: The role of GABA-B neurotransmission in addiction has recently received increased attention, with clinical trials indicating that baclofen, a GABA-B receptor agonist, may reduce alcohol consumption, craving and promote abstinence. However, the optimal dose to treat alcohol dependence is unclear with patients requesting and tolerating much higher doses (...) of baclofen, compared with other clinical uses. We assessed the pharmacokinetics and pharmacodynamics (PK/PD) of baclofen to provide insight into GABA-B sensitivity in this patient group, relative to controls. Methods: Male healthy volunteers (controls, n = 12) and abstinent alcohol dependent individuals (AD, n = 8) received single oral doses of baclofen or placebo in a 3-way crossover design. Controls received placebo/10 mg/60 mg baclofen in a randomized, double-blind design, AD received placebo/60 mg/90

2018 Frontiers in Psychiatry Controlled trial quality: uncertain

20. A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. Full Text available with Trip Pro

A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. Previous studies suggest that GABA-B receptor agonism may represent an effective pharmacological approach to treat addictive disorders. Baclofen is a selective GABA-B receptor agonist which has been investigated as a potential treatment for alcohol use disorder. However, research is needed to understand the biobehavioral mechanisms (...) underlying baclofen's effect on alcohol use. In the present randomized, double-blind, placebo-controlled study, thirty-four alcohol-dependent individuals were randomized to receive baclofen (30 mg/d) or placebo for a week, and then participated in a laboratory experiment consisting of three procedures: alcohol cue-reactivity, priming, and self-administration. During the experiment, craving and other subjective responses to alcohol were assessed, and blood samples were collected for pharmacokinetic

2018 Molecular psychiatry Controlled trial quality: uncertain